Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism? / Roviello, G., Buti, S., Cattrini, C., Mennitto, A., Messina, C., Airoldi, C., Vannini, G., Bersanelli, M.. - In: THERAPEUTIC ADVANCES IN UROLOGY. - ISSN 1756-2872. - 13:(2021), p. 17562872211029784. [10.1177/17562872211029784]
Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?
Buti S.;Bersanelli M.
2021-01-01
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
